Clinical trial registry record

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 21, 2021.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05110209
Last registry update
December 21, 2021
Status
Completed
Phase
Phase not reported
Sponsor
Novartis Pharmaceuticals
Enrollment
331541
Countries
United States
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
OBSERVATIONAL
Evidence population
Human clinical study registration
Participants
331541
Population
ALL · 18 Years to 85 Years
Duration
2020-07-15 to 2020-11-20
Intervention
Aflibercept; Ranibizumab; Bevacizumab
Comparator
Not reported
Outcomes measured
Number of patients with Intraocular Inflammation (IOI) Adverse events (AEs) who were treated with anti-VEGF agents — ea…; Age — earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019; Gender information — earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019; Number of patients at various Patient Region — earliest claim of anti-VEGF injection over a one-year period from 01/012…; Number of patients with Insurance type — earliest claim of anti-VEGF injection over a one-year period from 01/012019 to…; Number of patients with Laterality of wet Age-related macular degeneration (AMD) — Index date (defined as the date of f…; Number of patient eyes with the Provider specialty on date of first anti-VEGF injection — earliest claim of anti-VEGF i…; Number of patient eyes treated with anti-VEGF agent — Index date (defined as the date of first injection - 01/01/2019); Number of anti-VEGF injections — over a one-year period from 01/012019 to 31/12/2019; Number of patients with other ocular AEs in patients with wet AMD who were treated with anti-VEGF agents (excluding bro…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON